Molecular Studies on Pasteurella multocida in Ducks

Abstract

Pasteurella multocida is the common cause of Duck septicemia (Pasteurellosis) which affects ducks leading to high economic losses to duck producers. Pasteurella multocida infections are associated with severe, life-threatening systemic disease involving both hemorrhagic pneumonia and septicemia. A cross-sectional study was carried out on 220 samples collected from different breeds of ducks (Mallard, Muscovy and Baladi) from Minufiya governorate, Egypt. Only 16 cases were positive for Pasteurella multocida infection (7.3%). These isolates were confirmed microscopically, biochemically and rapidly by using Vitek2 compact system. The application of PMT-ELISA and mouse lethality test for the 16 isolates of P.multocida serotypes for differentiation between toxigenic and non toxigenic isolates. All tested of 16 isolates showed to be toxigenic by using PMT-ELISA and mouse lethality test. The application of PCR and multiplex PCR for the detection of tox A gene and capsular serotyping of toxigenic isolates of P.multocida respectively. All 16 P.multocida isolates were positive to tox A and capsular type A (100%). This study concluded that P. multocida serve as a major cause of Duck septicemia (Pasteurellosis) which affects ducks leading to high economic losses in poultry industry. Also indicated that the majority of P. multocida serotypes are toxigenic.

Pathognomonic features of Pasteurella multocida isolates among various avian species in Sharkia Governorate, Egypt

“…The majority were of capsular type A (96.6%; 29/30). This is consistent with other studies (Mohamed and Mageed 2014 ; Abd-Elsadek et al 2021 ; Shalaby et al 2021 ) which isolated P. multocida in nearly similar percentages and found capsular type A to be the most common capsular type among avian strains. Interestingly, capsular type D was detected in 3.4% (1/30) of isolated P. multocida from quails, a serogroup considered rare (Glisson et al 2008 ), demonstrating a variable prevalence of the serogroups in cases of respiratory disease according to the geographic region (Davies et al 2003 ).…”

Global commercialization and research of veterinary vaccines against Pasteurella multocida: 2015–2022 technological surveillance

“…The results of Almoheer et al [27] shows similarity with other studies conducted during 2005-2019, which may partly be because of the global distribution of the pathogen, its ability to cause mass mortality events, and the diversity of affected animals [4][5][6][52][53][54][55][56][57][58]. From the economic standpoint, it reflects the enormous pressure to minimize losses while raising productive animals and the need to meet the sustained increase in the global demand for animal protein [48].…”

Pasteurellosis Vaccine Commercialization: Physiochemical Factors for Optimum Production

“…Bacteria can enter the bloodstream from the mucosa and multiply in many organs, particularly the liver and spleen, via an unknown process that is probably connected to movement in URT macrophages [2]. P. multocida may be verified microscopically, biochemically, and quickly using the Vitek2 compact system, an enzyme-linked immunosorbent test (ELISA), mouse lethality bioassay, and a polymerase chain reaction (PCR) [15]. In addition, matrix-assisted laser desorption/ionization timeof-flight mass spectrometry (MALDI-TOF) has been identified as a quick and dependable alternative method for differentiating most members of the Pasteurellaceae family [16].…”